
Scribe Therapeutics Inc. (NASDAQ:SCTX – Free Report) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for Scribe Therapeutics in a research note issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($4.60) for the year, down from their prior forecast of ($3.68). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Scribe Therapeutics’ current full-year earnings is ($3.68) per share. HC Wainwright also issued estimates for Scribe Therapeutics’ Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.58) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.71) EPS, Q4 2027 earnings at ($0.80) EPS and FY2027 earnings at ($2.71) EPS.
A number of other brokerages also recently weighed in on SCTX. Guggenheim initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $50.00 price target on the stock. Zacks Research upgraded Scribe Therapeutics to a “hold” rating in a research note on Tuesday, September 1st. Leerink Partners began coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 price objective for the company. Wells Fargo & Company initiated coverage on Scribe Therapeutics in a research note on Tuesday, August 18th. They set an “overweight” rating and a $60.00 target price for the company. Finally, Weiss Ratings began coverage on Scribe Therapeutics in a report on Tuesday, October 20th. They set a “sell (e-)” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.75.
Check Out Our Latest Analysis on SCTX
Scribe Therapeutics Price Performance
Shares of NASDAQ:SCTX opened at $15.37 on Tuesday. Scribe Therapeutics has a 52-week low of $13.50 and a 52-week high of $39.60. The firm has a market cap of $290.98 million and a P/E ratio of -1.41. The firm has a 50-day moving average price of $20.86.
Scribe Therapeutics (NASDAQ:SCTX – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). The firm had revenue of $1.64 million for the quarter.
Institutional Trading of Scribe Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP bought a new position in Scribe Therapeutics in the 3rd quarter valued at about $12,675,000. Goldman Sachs Group Inc. acquired a new stake in Scribe Therapeutics during the third quarter worth approximately $398,000. Finally, State Street Corp bought a new stake in shares of Scribe Therapeutics during the third quarter worth approximately $3,150,000.
Scribe Therapeutics Company Profile
Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.
Read More
- Five stocks we like better than Scribe Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
